Merosin deficient congenital muscular dystrophy type 1A: An international workshop on the road to therapy 15-17 November 2019, Maastricht, the Netherlands
Neuromuscul Disord. 2021 Jul;31(7):673-680.
doi: 10.1016/j.nmd.2021.04.003.
Epub 2021 May 1.
1 Department of Toxicogenomics, Research Schools GROW and MHeNS, Maastricht University, Maastricht, The Netherlands. Electronic address: bert.smeets@maastrichtuniversity.nl.
2 MDC1A Foundation "Voor Sara", Dordrecht, The Netherlands.
3 Maastricht University, The Netherlands.
4 Department of Neurology, Radboud University Medical Center, Nijmegen, The Netherlands.
5 University of Manchester, Manchester, UK.
6 Maastricht University, Maastricht, NL.
7 Lund University, Lund, SE.
8 Cure CMD, San Diego, US.
9 RadboudUMC, Nijmegen, NL.
10 NIH, Bethesda, USA.
11 University of Massachusetts Medical School, Worcester, US.
12 Children's Hospital of Pittsburgh, Pittsburgh, US.
13 University of Zürich, Zürich, CH.
14 IRCCS San Raffaele Scientific Institute Milan, IT.
15 University of Basel, Basel, CH.
16 KU Leuven, Leuven, BE.
17 Dubowitz Neuromuscular Centre, London, UK.
18 University of Cincinnati, Cincinnati, US.
19 Patient representative, Amsterdam, NL.
20 Patient representative, Groningen, NL.
21 Hacettepe University School of Medicine, Ankara, TR.
22 Robert Wood Johnson Medical School, Piscataway, US.